Acetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP)

Prior treatment

• Receive cytotoxic therapy for primary or secondary kidney disease within 6 months prior to enrollment
• Organ Transplant History
• Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrollment

Other illness

• Class IV congestive heart failure (New York Heart Association)
• Any condition outside the realm of renal and cardiovascular disease, such as, but not limited to, malignancy, with a life expectancy of less than 2 years in the clinical judgment of the investigator
• Active malignancy requiring treatment at Visit 1 (except successfully treated basal or squamous cell carcinoma).

Lab values

• Hepatic impairment (aspartate transaminase or alanine transaminase \>3x upper limit of normal; or total bilirubin \>2x upper limit of normal at time of enrollment

Other

• Coronary revascularization (percutaneous coronary intervention or arterial bypass) or valve repair/replacement within 12 weeks of enrollment or is scheduled to undergo one of these procedures within 4 weeks of enrollment
• Pregnancy or lactation
• Adherence to a ketogenic diet, consumption of ketogenic products or supplements or intermittent fasting or other diet or supplements that may significantly increase ketones in the past two months.
• Daily alcohol consumption \>2 servings per day
• Participation in other interventional research projects concurrently or participation in other PET research projects in the last year, which exceeds the recommended limits
• Inability to lie still in supine position;
• Medical fluid restriction limiting fluid intake for the procedure

• BMI between 18.5 and 40
• Kidney failure if GFR betweem 30 and 60 mL/min/1.73m2
• Stable medication for at least 4 weeks